Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?
Dr. Thomas John of the Olivia Newton-John Cancer Center in Melbourne, Australia presents his favorite breakthroughs in lung cancer from 2014.
For those who wish to access the PDF, it's here: Thomas John, MD Top Four Lung Cancer Highlights 2014
Agree? Disagree? What are you looking forward to in 2015?
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Lung cancer patients with high MET amplification appear to do well on Xalkori (crizotinib), a drug that is approved for ALK positive patients.
Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.
MARQUEE Trial of MET Inhibitor Tivantinib (ARQ-197) Negative for Survival Benefit, But OS Benefit Seen in MET-Positive Patients
Almost exactly a year ago, I reported that the large MARQUEE trial of EGFR inhibitor Tarceva (erlotinib) plus either the MET inhibitor tivantinib (ARQ-197) or placebo as second or third line treatment for advanced NSCLC had been discontinued after a planned interim analysis revealed that it wouldn't be statistically significantly superior for overall survival (OS), the primary endpoint of the trial.
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. David Spigel from Sarah Cannon Cancer Center offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
One of the more promising agents for advanced NSCLC in the last few years has been the oral Met inhibitor tivantinib, also known as ARQ-197.